Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The study hypothesis is that chemoradiation based on 2 drugs will improve local control and
long-term survival in patients with locally advanced pancreatic cancer. That is why
gemcitabine and irinotecan are combined in an induction phase of 2 months and then this
IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with
irradiation.